Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Extends Listing Deadline for Pressure BioSciences

NEW YORK (GenomeWeb News) – A Nasdaq panel has granted Pressure BioSciences' request for continued listing on the exchange, the company said today.

The Nasdaq Listing Qualifications Panel told Pressure Bio of its decision on Dec. 7 to allow the company to remain listed on the Nasdaq Capital Market until Feb. 29, 2012, subject to certain conditions, including the company's demonstration of compliance with a listing requirement to have at least $2.5 million in stockholder equity.

Pressure Bio was originally warned by Nasdaq in April that it was in danger of being delisted because of its failure to meet that requirement, and had until June to regain compliance.

The deadline was then extended to October, and after the company failed to regain compliance it requested a hearing with the Nasdaq panel.

Pressure Bio faces possible delisting action on another requirement calling for a minimum bid price on its shares of $1 for at least 30 consecutive business days. It has until Feb. 13, 2012 to regain compliance with that condition.

Faced with an evaporating cash position, the South Easton, Mass.-based firm earlier this week filed a registration form with the US Securities and Exchange Commission to raise up to $8 million.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.